Reuters logo
BRIEF-Achaogen starts C-Scape clinical development program with phase 1 study of orally-administered antibacterial candidate
June 1, 2017 / 12:20 PM / 6 months ago

BRIEF-Achaogen starts C-Scape clinical development program with phase 1 study of orally-administered antibacterial candidate

June 1 (Reuters) - Achaogen Inc

* Initiates c-scape clinical development program with phase 1 study of orally-administered antibacterial candidate

* Says preclinical studies have confirmed c-scape’s potent in vitro microbiologic activity against esbl-producing enterobacteriaceae Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below